A3P

Log in

Pharmaceutical industry: France less attractive than its neighbors

The attractiveness and accessibility of France for investments in health are short of some of its European neighbors, according to a study by Roland Berger unveiled Wednesday, which lists 110 proposals to remedy.

Read more...

Cytotec, a drug diverted from its use, withdrawn from the market in 2018

Cytotec, a drug against stomach ulcer, diverted to trigger eventual deliveries at the risk of maternal and child health, will be withdrawn from the French market as of March 2018, Drug Agency.

Read more...

Sanofi invests 170 million euros to expand a production site in Normandy

The pharmaceutical giant Sanofi will invest 170 million euros to expand its site in Val-de-Reuil (Eure), specializing in the production of vaccines, especially against the flu, he announced Thursday.

Read more...

USA: FDA approves gene therapy for aggressive lymph nodes

The US Food and Drug Administration (FDA) on Wednesday approved the second worldwide gene therapy, Yescarta, to treat aggressive non-Hodgkin's lymphoma, a tumor of the lymphatic system.

Read more...

Pfizer plans to sell its non-prescription drug division

The US pharmaceutical company Pfizer on Tuesday announced plans to study several scenarios for the future of its over-the-counter medicines division, including its outright sale.

Read more...

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P